A boy, suffering from Malaria, recovers at a clinic in Mogadishu, Somalia.
Photo: © Tobin Jones /flickr


<< First < Previous Page 1 Page 2 Next > Last >>
The malaria vaccine Mosquirix receives positive scientific opinion from EMA in July 2015. It could be used for vaccination of young children, together with established antimalarial interventions.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive scientific opinion for Mosquirix (Plasmodium falciparum and hepatitis B vac-cine), for use outside the European Union (EU). This was reported by the European Medicines Agency (EMA) in July 2015.

Mosquirix is intended for use in areas where malaria is regularly found, for the active immunisation of children aged 6 weeks to 17 months against malaria caused by the Plasmodium falciparum parasite, and against hepatitis B. After decades of research into malaria vaccinations, Mosquirix is the first vaccine for the disease to be assessed by a regulatory agency.

The CHMP highlighted in its opinion that Mosquirix is for use in line with official recommendations that take into account the risk of Plasmodium falciparum malaria in different geographical areas and available malaria control interventions. These recommendations will be defined by the World Health Organization (WHO) and regulatory authorities in the non-EU countries where the vaccine would be used.

About Mosquirix

According to evidence derived from a large clinical trial conducted in seven African countries (Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and Tanzania); Mosquirix provides modest protection against Plasmodium falciparum malaria in children in the 12 months following vaccination.

<< First < Previous Page 1 Page 2 Next > Last >>